Chennai Journal

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 24
14:55 2021
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Progressive Familial Intrahepatic Cholestasis (PFIC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Progressive Familial Intrahepatic Cholestasis (PFIC) , historical and forecasted epidemiology as well as the Progressive Familial Intrahepatic Cholestasis (PFIC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Progressive Familial Intrahepatic Cholestasis (PFIC) – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Progressive Familial Intrahepatic Cholestasis (PFIC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Progressive Familial Intrahepatic Cholestasis (PFIC), historical and forecasted epidemiology as well as the  Progressive Familial Intrahepatic Cholestasis (PFIC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. According to a French study, the estimated incidence varies between 1 per 50,000 and 1 per 100,000 birthsin the PFIC patients. It was also found that PFIC1 and PFIC2 represented two out of three cases of total PFIC, whereas PFIC3 as one case per three cases. 

  2. The United Kingdom-based study found that the incidence of intrahepatic cholestasis was 1 per 18,000 live births. The researchers also referred to a study in which infants and children (2–18 years) with cholestasis were 12–13% with genetically diagnosed PFIC.

Key benefits of the report:

1. Progressive Familial Intrahepatic Cholestasis (PFIC) market report covers a descriptive overview and comprehensive insight of the Progressive Familial Intrahepatic Cholestasis (PFIC) epidemiology and Progressive Familial Intrahepatic Cholestasis (PFIC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Progressive Familial Intrahepatic Cholestasis (PFIC) market report provides insights on the current and emerging therapies.

3. Progressive Familial Intrahepatic Cholestasis (PFIC) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Progressive Familial Intrahepatic Cholestasis (PFIC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Progressive Familial Intrahepatic Cholestasis (PFIC) market.

Request for sample pages: https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

Progressive Familial Intrahepatic Cholestasis (PFIC): Overview

Progressive familial intrahepatic cholestasis (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure. In people with PFIC, liver cells are less able to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals.

The key players involved in the Progressive Familial Intrahepatic Cholestasis (PFIC) market:

  1. Mirum Pharmaceuticals

  2. Albireo

  3. Vivet Therapeutics 

The launch of the emerging therapies is expected to significantly impact the  Progressive Familial Intrahepatic Cholestasis (PFIC) treatment scenario in the upcoming years:-

Drug covered

  1. Maralixibat (LUM001/ SHP625) 

  2. A4250 (odevixibat)

  3. VTX-802 and VTX-803

Request a free sample report @https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Progressive Familial Intrahepatic Cholestasis (PFIC) Patient Share (%) Overview at a Glance

5. Progressive Familial Intrahepatic Cholestasis (PFIC) Market Overview at a Glance

6. Progressive Familial Intrahepatic Cholestasis (PFIC) Disease Background and Overview

7. Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology and Patient Population

8. Country-Specific Patient Population of Progressive Familial Intrahepatic Cholestasis (PFIC)

9. Progressive Familial Intrahepatic Cholestasis (PFIC) Current Treatment and Medical Practices

10. Unmet Needs

11. Progressive Familial Intrahepatic Cholestasis (PFIC) Emerging Therapies

12. Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook

13. Country-Wise Progressive Familial Intrahepatic Cholestasis (PFIC) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Progressive Familial Intrahepatic Cholestasis (PFIC) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Progressive Familial Intrahepatic Cholestasis (PFIC)- Pipeline Insights, 2021

“Progressive Familial Intrahepatic Cholestasis (PFIC)- Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Progressive Familial Intrahepatic Cholestasis (PFIC) market. A detailed picture of the Progressive Familial Intrahepatic Cholestasis (PFIC) pipeline landscape is provided, which includes the disease overview and Progressive Familial Intrahepatic Cholestasis (PFIC) treatment guidelines.

Progressive Familial Intrahepatic Cholestasis (PFIC) -Epidemiology Forecast to 2030

DelveInsight’s ‘Progressive Familial Intrahepatic Cholestasis (PFIC) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Progressive Familial Intrahepatic Cholestasis (PFIC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles